-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in US stocks | Three tests failed in a row in a week, Novartis Pharmaceuticals (NVS.US) plummeted by more than 12%

Zhitongcaijing·09/09/2026 08:25:18
Listen to the news

The Zhitong Finance App learned that on Tuesday, Novartis Pharmaceuticals (NVS.US) plummeted by more than 12% at the beginning of the session and is now reported at $139.13. According to the news, Novartis experienced a third clinical trial setback in just one week. The Swiss pharmaceutical company said on Tuesday that its experimental injectable drug Del-Desiran for treating type 1 muscular dystrophy (DM1, a rare muscle atrophy disease) failed to reach a major end in the Phase III Harbor study.

The data showed no statistically significant improvement in patients' video hand opening time (vHOT) compared to placebo. Novartis Pharmaceuticals said that the study observed secondary endpoints and signs of clinical activity in exploratory analysis, and overall safety was consistent with previous data. The company will further analyze the complete data and determine the subsequent development path after communicating with regulators.